CLINICAL TRIALS PROFILE FOR MOXIFLOXACIN HYDROCHLORIDE

505(b)(2) Clinical Trials for moxifloxacin hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT01589497 ↗	Essentiality of INH in TB Therapy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2015-06-30	Tuberculosis (TB) disease is caused by bacteria that have infected the lung. TB bacteria are very small living agents that are spread by coughing and can be killed by taking TB drugs. To kill these TB bacteria TB patients have to take a combination of four drugs for 2 months and then two drugs for a further 4 months. During the first 2 months patients take rifampicin, isoniazid, ethambutol, and pyrazinamide. After that patients take only isoniazid and rifampicin for a further 4 months, making a total of 6 months therapy. In A5307 the investigators wanted to test a new combination of drugs to see if the investigators could treat TB faster in the future. Studies in animals have suggested that one of the four drugs, isoniazid, only works for a few days and may not be needed after the first two doses of TB treatment to kill the TB bacteria. After that its effects wear off to the point that it may even interfere with the other drugs. The investigators wanted to see if stopping isoniazid early, or using moxifloxacin, a different drug, instead could treat TB faster. This study was the first time that this type of regimen without isoniazid had been tested in humans. If the investigators could show that isoniazid stops working after a few days, the investigators could then try to see if they could possibly make a better tuberculosis treatment in the future.
New Combination	NCT01589497 ↗	Essentiality of INH in TB Therapy	Completed	AIDS Clinical Trials Group	Phase 2	2015-06-30	Tuberculosis (TB) disease is caused by bacteria that have infected the lung. TB bacteria are very small living agents that are spread by coughing and can be killed by taking TB drugs. To kill these TB bacteria TB patients have to take a combination of four drugs for 2 months and then two drugs for a further 4 months. During the first 2 months patients take rifampicin, isoniazid, ethambutol, and pyrazinamide. After that patients take only isoniazid and rifampicin for a further 4 months, making a total of 6 months therapy. In A5307 the investigators wanted to test a new combination of drugs to see if the investigators could treat TB faster in the future. Studies in animals have suggested that one of the four drugs, isoniazid, only works for a few days and may not be needed after the first two doses of TB treatment to kill the TB bacteria. After that its effects wear off to the point that it may even interfere with the other drugs. The investigators wanted to see if stopping isoniazid early, or using moxifloxacin, a different drug, instead could treat TB faster. This study was the first time that this type of regimen without isoniazid had been tested in humans. If the investigators could show that isoniazid stops working after a few days, the investigators could then try to see if they could possibly make a better tuberculosis treatment in the future.
New Indication	NCT03257423 ↗	Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects	Enrolling by invitation	Helsinki University Central Hospital	N/A	2017-04-04	Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings. On the other hand, antibiotic therapies have been shown to have an effect on the normal gut microbiota and are considered an increasing global health threat underlining the importance of evaluating both short- and long-term effects of the antimicrobial treatment in old and new indications. The aims of this randomized prospective study are: 1. To evaluate the possible role and differences in the microbiological etiology of complicated and uncomplicated appendicitis. 2. To determine the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment (AMT) 3. To evaluate the effects of the duration of the hospital stay on the AMR reservoir of the gut microbiota.
New Indication	NCT03257423 ↗	Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects	Enrolling by invitation	Jyväskylä Central Hospital	N/A	2017-04-04	Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings. On the other hand, antibiotic therapies have been shown to have an effect on the normal gut microbiota and are considered an increasing global health threat underlining the importance of evaluating both short- and long-term effects of the antimicrobial treatment in old and new indications. The aims of this randomized prospective study are: 1. To evaluate the possible role and differences in the microbiological etiology of complicated and uncomplicated appendicitis. 2. To determine the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment (AMT) 3. To evaluate the effects of the duration of the hospital stay on the AMR reservoir of the gut microbiota.

All Clinical Trials for moxifloxacin hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00062231 ↗	Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer	Terminated	European Organisation for Research and Treatment of Cancer - EORTC	N/A	2002-04-01	RATIONALE: Antibiotics such as amoxicillin, ciprofloxacin, and moxifloxacin may be effective in preventing or controlling fever and neutropenia in patients with cancer. It is not yet known whether moxifloxacin alone is more effective than amoxicillin combined with ciprofloxacin in treating neutropenia and fever. PURPOSE: This randomized clinical trial is studying how well moxifloxacin works and compares it to ciprofloxacin together with amoxicillin in treating neutropenia and fever in patients with cancer.
NCT00082173 ↗	Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis	Completed	Johns Hopkins University	Phase 2	2004-10-01	Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively treat TB.

Clinical Trial Conditions for moxifloxacin hydrochloride

Condition Name

Condition Name for moxifloxacin hydrochloride
Intervention	Trials
Healthy	92
Healthy Volunteers	31
Tuberculosis	23
Healthy Subjects	20

Condition MeSH

Condition MeSH for moxifloxacin hydrochloride
Intervention	Trials
Tuberculosis	58
Tuberculosis, Pulmonary	33
Cataract	24
Infections	23

Clinical Trial Locations for moxifloxacin hydrochloride

Trials by Country

Trials by Country for moxifloxacin hydrochloride
Location	Trials
United States	512
South Africa	113
Germany	100
China	89
United Kingdom	60

Trials by US State

Trials by US State for moxifloxacin hydrochloride
Location	Trials
Texas	57
California	35
Florida	32
Arizona	31
Maryland	28

Clinical Trial Progress for moxifloxacin hydrochloride

Clinical Trial Phase

Clinical Trial Phase for moxifloxacin hydrochloride
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	7
PHASE2	4

Clinical Trial Status

Clinical Trial Status for moxifloxacin hydrochloride
Clinical Trial Phase	Trials
Completed	365
Recruiting	64
Not yet recruiting	28

Clinical Trial Sponsors for moxifloxacin hydrochloride

Sponsor Name

Sponsor Name for moxifloxacin hydrochloride
Sponsor	Trials
Bayer	34
GlaxoSmithKline	20
Pfizer	18

Sponsor Type

Sponsor Type for moxifloxacin hydrochloride
Sponsor	Trials
Other	476
Industry	442
NIH	16

Moxifloxacin Hydrochloride: Clinical Trial Update, Market Analysis, and Projection

Last updated: April 24, 2026

What does the clinical trial landscape show for moxifloxacin hydrochloride?

Moxifloxacin hydrochloride is an established fluoroquinolone antibiotic with long-standing global approvals for multiple indications. The clinical-trial ecosystem is no longer dominated by new “first-in-class” development; activity centers on post-approval work such as formulation updates, comparative studies, and incremental label expansions, typically in acute bacterial infection settings where endpoints and regulatory pathways are well characterized.

Where trials appear most often

Trial activity for moxifloxacin hydrochloride typically clusters around:

• Respiratory and ENT bacterial infections (community-acquired bacterial pneumonia, acute bacterial sinusitis)
• Skin and skin structure infections where fluoroquinolone regimens are studied as comparators
• Gynecologic/intra-abdominal infection contexts in subsets of regional programs
• Formulation and route comparisons (oral versus IV, or bioequivalence-style studies)

What is most likely to drive current enrollments

Given the maturity of the drug class and compound, the dominant trial mechanics are:

• Randomized comparative studies against standard-of-care antibiotics
• Non-inferiority designs using established clinical cure and microbiological eradication endpoints
• Pharmacokinetic and tolerability studies tied to formulation or patient population coverage
• Regimen studies that validate placement in treatment pathways rather than create new mechanisms

How big is the moxifloxacin hydrochloride market and what segments matter most?

Moxifloxacin hydrochloride competes in the broad fluoroquinolone and broader anti-infectives universe. The market is shaped by three forces: (1) the established prescriber comfort and guideline inclusion of fluoroquinolones in selected settings, (2) safety-focused prescribing scrutiny for fluoroquinolones in certain patient groups, and (3) the growth of hospital and outpatient antimicrobial stewardship frameworks that manage use intensity.

Market structure (practical segmentation for investors)

For commercial planning, the market breaks most usefully into:

• Geographies: US, EU5, UK, Japan, China, and “rest of world” (emerging tender-driven demand)
• Care settings: hospital/acute care versus outpatient/community
• Form factors: oral tablets, IV/oral switching pathways, and branded versus generic pricing tiers
• Indication bundles: respiratory infections and acute bacterial ENT remain the core demand pools

Branded-to-generic dynamic

Moxifloxacin’s patent status and age in most major markets have driven generic penetration. Commercial outcomes now depend more on:

• Tender access and contracting (especially hospital channels)
• Line-of-supply robustness (manufacturing capacity and regulatory compliance)
• Price positioning against other fluoroquinolones and non-fluoroquinolone alternatives
• Channel mix between oral and IV (hospital protocols and switch strategies)

Competitive set (how moxifloxacin is typically priced and defended)

Moxifloxacin competes primarily with:

• Other fluoroquinolones used for similar respiratory and skin indications
• Beta-lactams, macrolides, and other guideline-supported antibiotics where stewardship restricts fluoroquinolone use

In mature markets, the “winning” metric is usually cost-per-treated-case and availability, not clinical differentiation.

What is the projection outlook for demand and revenue?

A forward projection for moxifloxacin hydrochloride must reflect that:

• The compound is mature
• Uptake depends on guideline placement and antibiotic stewardship pressure
• Growth is more likely to come from volume stability plus market access than from new indication-driven step changes

Base-case trajectory (qualitative market mechanics)

A realistic projection framework for moxifloxacin hydrochloride in 2025-2030 should assume:

• Moderate volume growth or flat volume in most mature geographies driven by population needs in acute infections, offset by stewardship restrictions
• Pricing pressure continues in generic-heavy markets, limiting revenue growth unless supply-side advantages or channel wins occur
• Growth pockets exist where hospital formularies and tender procurement sustain consistent procurement volume

Key sensitivities

Revenue and demand outcomes are sensitive to:

• Regulatory and label updates that shift fluoroquinolone prescribing behavior
• Antibiotic stewardship policies that tighten fluoroquinolone initiation thresholds
• Generic competition intensity by region and tender season
• Supply stability and quality recalls in the broader anti-infectives supply chain

Market projections by region: directional view

This section provides a directional projection map, aligned to typical procurement and prescribing patterns for an established generic antibiotic.

Region	Demand outlook	Revenue outlook	Primary driver
US	Flat to slight down (stewardship impact)	Flatter (price compression offsets volume)	Guideline restraint and generic competition
EU5 + UK	Stable to slight down	Stable (tender-driven pricing)	Hospital procurement discipline
Japan	Stable	Stable to slight up	Formularies and controlled prescribing
China	More resilient volume	Slight growth possible	Hospital demand plus tender procurement
Rest of world	Variable by country	Moderate volatility	Access, distribution strength, procurement cycles

What do “clinical trial updates” mean for investors now?

For a mature antibiotic, “updates” are less about mechanism novelty and more about:

• New comparative regimens that reinforce placements in local treatment pathways
• Formulation or PK refreshers that preserve market access
• Regional label maintenance and post-authorization evidence gaps

These activities can still affect market outcomes at the margin by sustaining formulary inclusion and procurement eligibility.

Business implications: where value is likely to accrue

For moxifloxacin hydrochloride, the highest-probability value capture is operational:

• Contracting and tender wins where clinicians and hospital committees already have fluoroquinolone frameworks
• Manufacturing scale and compliance to maintain uninterrupted supply
• Portfolio management across IV-to-oral sequences that align with hospital switch protocols
• Regional go-to-market tuned to procurement cycles

Key Takeaways

• Moxifloxacin hydrochloride remains a mature antibiotic with clinical activity dominated by incremental comparative, formulation, and regimen studies, not major mechanism-changing innovation.
• Market demand tracks acute infection burden but revenue growth is constrained by generic pricing pressure and stewardship-driven prescribing limits.
• Near-term projections should assume flat-to-moderate volume and limited revenue upside in most mature markets, with more favorable outcomes tied to tender access and supply strength in select geographies.
• Commercial advantage is more operational than scientific: hospital contracting, manufacturing reliability, and channel mix (IV versus oral) determine results more than differentiation.

FAQs

1) Is moxifloxacin hydrochloride still being developed in major clinical programs?

Clinical activity exists but is largely incremental and post-approval, typically focused on comparative evidence, formulation, and regimen validation rather than new drug-class discovery.

2) What endpoints drive clinical studies for moxifloxacin today?

Commonly used endpoints include clinical cure and microbiological eradication under established non-inferiority or comparative frameworks aligned to infection indications.

3) What most affects market revenue for moxifloxacin in generic-heavy markets?

Generic competition drives pricing compression, so revenue is most sensitive to tender volume, procurement contracting, and supply continuity.

4) Do stewardship restrictions change the demand profile?

Yes. Stewardship programs can reduce initiation frequency for fluoroquinolones in certain patient groups or settings, shifting demand between indications and care settings.

5) Where is growth most likely compared with mature markets?

Regions with resilient hospital procurement and less intense price compression can show relatively better demand and revenue dynamics, assuming supply and contracting strength.

---

References

[1] FDA. (n.d.). Drugs@FDA: FDA-approved drugs (Moxifloxacin-related entries). Food and Drug Administration.
[2] EMA. (n.d.). European public assessment reports (EPAR) for moxifloxacin medicines. European Medicines Agency.
[3] WHO. (n.d.). WHO model list of essential medicines (fluoroquinolone antibiotic positioning). World Health Organization.
[4] ClinicalTrials.gov. (n.d.). moxifloxacin hydrochloride clinical trials registry search results. National Library of Medicine.
[5] IDSA. (n.d.). Guidelines on the treatment of bacterial infections (fluoroquinolone placement and stewardship principles). Infectious Diseases Society of America.